{"id": "826494ca4da22c5f-FRA", "status": "finished", "prompt": ["<s>[INST] <<SYS>>\nYou are an expert annotator for outputs of text simplification systems. You are given an example, a sample to annotate and detailed instructions.\n<</SYS>>\n\n\n### Original\nThis study evaluates the effects of vitamin D3 on disease activity and quality of life in ulcerative colitis (UC) patients with hypovitaminosis D. The study was a prospective double-blinded, randomized trial conducted at Community Regional Medical Center, Fresno, CA from 2012\u20132013. Patients with UC and a serum 25(OH)D level <30 ng/ml were eligible for the study. Enrolled subjects were randomized to receive either 2,000 lU or 4,000 IU of oral vitamin D3 daily for a total of 90 days. The Short IBD Questionnaire (SIBDQ) for quality of life, the Partial Mayo Score for UC disease activity and serum lab tests were compared between the two treatment groups.\n\n### Simplification\nThis study looks at whether taking vitamin D3 can affect a particular form of bowel disease (ulcerative colitis) and improve the lives of patients with low levels of vitamin D. The study was carried out at a medical center in Fresno, California, between 2012 and 2013. Patients with this disease and low vitamin D levels were included. Participants were randomly given either 2,000 IU or 4,000 IU of oral vitamin D3 daily for 90 days. Researchers used a survey about participant's quality of life and conducted lab tests between the two groups.\n\n### Missing information in simplification [/INST] [\n    {\n        \"category\": \"imprecise/fuzzy concepts\",\n        \"original\": \"The study was a prospective double-blinded, randomized trial\",\n        \"simplification\": \"The study\",\n        \"rationale\": \"The simplification does not explain the design of the study, it only mentions that it was a 'study'.\",\n        \"question\": \"How did the study control for bias?\",\n        \"answer\": \"The study was double-blinded, so that neither the researcher nor the participants knew which treatment each participant received, and it was randomized, meaning the participants were randomly assigned one of the treatments.\",\n    },\n    {\n        \"category\": \"imprecise/fuzzy concepts\",\n        \"original\": \"a serum 25(OH)D level <30 ng/ml\",\n        \"simplification\": \"low vitamin D levels\",\n        \"rationale\": \"The simplification does not explain the inclusion criteria, namely how low the vitamin D levels of eligible patients were.\",\n        \"question\": \"How low were the vitamin D levels in patients that were included in the study?\",\n        \"answer\": \"Participants in the study all had less than 30ng/ml of vitamin D, which is below the minimum recommendation of vitamin D levels in the body.\"\n    },\n    {\n        \"category\": \"imprecise/fuzzy concepts\",\n        \"original\": \"Short IBD Questionnaire (SIBDQ) for quality of life\",\n        \"simplification\": \"a survey about participant's quality of life\",\n        \"rationale\": \"The specific type of survey (SIBDQ) is not mentioned in the simplification\",\n        \"question\": \"What survey was used to measure participants' quality of life?\",\n        \"answer\": \"The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) was used which gives insights about the physical, social, and emotional status of patients with bowel diseases.\",\n    },\n    {\n        \"category\": \"omission\",\n        \"original\": \"Partial Mayo Score for UC disease activity\",\n        \"simplification\": null,\n        \"rationale\": \"The simplification does not mention that the Partial Mayo Score was used.\",\n        \"question\": \"Besides quality of life survey and the serum tests, what other measures did the researchers use?\",\n        \"answer\": \"The researchers also tracked the partial mayo for UC diseases. UC stands for ulcerative colitis and is an inflammatory bowel disease. The mayo score indicates how active or severe the disease is.\",\n    },\n] </s><s>[INST] ### Original\nBACKGROUND.\nLocally advanced pancreatic cancer (LAPC) is associated with high mortality, and biomarker-driven treatment approach is currently lacking. This study evaluated safety and efficacy of a combination approach of chemotherapy followed by chemo-radiotherapy (CRT) +/\u2212 cetuximab, and the prognostic role of miR-21 in patients with LAPC treated with a multimodality approach.\n\nPATIENTS AND METHODS.\nThis was a randomised phase II trial in which patients with inoperable LAPC were offered gemcitabine and capecitabine (GEM-CAP) for 16 weeks. Patients with stable disease or response after GEM-CAP were randomised to capecitabine or UFT plus radiotherapy (RT) (A), or capecitabine or UFT plus cetuximab plus RT (B). The primary outcome of the study was overall survival (OS). Clinical outcome was compared according to baseline circulating miR-21 levels.\n\nRESULTS.\n17 patients were enrolled and treated with GEM-CAP, with 13 patients achieving disease control and being randomised to arms A (n:7) and B (n:6). After a median follow-up of 61.2 months, median progression free survival (PFS) was 10.4 months and 12.7 months, median OS was 15.8 months and 22.0 months in arms A and B respectively (p > 0.05). Patients with high baseline plasma miR-21 had worse PFS (3.5 vs. 12.7 months; p:0.032) and OS (5.1 vs 15.3 months; p:0.5) compared to patients with low miR-21. Circulating miR-21 levels reflected miR-21 expression within the tissues.\n\nCONCLUSIONS.\nAddition of Cetuximab to CRT following induction chemotherapy did not improve survival. High miR-21 baseline plasma expression was associated with poor clinical outcome in LAPC patients treated with induction chemotherapy followed by chemo-radiotherapy.\n\n### Simplification\nBACKGROUND.\nThis research focused on a type of pancreatic cancer that is hard to treat and often results in death. Specifically, it tested if a combined treatment of chemotherapy and chemo-radiotherapy with or without an extra drug called cetuximab would help. It also checked if a biomarker (something in your body that can be measured to show the presence of disease), called miR-21, could predict how patients would respond to the treatment.\n\nPATIENTS AND METHODS.\nIn this trial, patients who couldn't undergo surgery for their pancreatic cancer were given a specific combination of drugs for 16 weeks. Only patients whose cancer didn't worsen or even improved after this initial treatment were then given another drug either with or without cetuximab in combination with radiotherapy. The key measure of success was overall survival rate. They also compared people's response to the treatment based on their levels of the biomarker miR-21.\n\nRESULTS.\n17 patients took the initial drugs, and 13 of them improved enough to receive the extra treatments. After about 5 years, they recorded how long it took for patients' cancers to get worse and how long the patients lived overall. They didn't see a big difference whether patients received the extra drug cetuximab or not. They did find that patients with high levels of the biomarker miR-21 generally did worse compared to those with lower levels, in terms of both how quickly their cancer got worse and how long they lived.\n\nCONCLUSIONS.\nAdding cetuximab to the chemo-radiotherapy after the initial combination drug treatment didn't seem to improve survival rates. Having a high level of the miR-21 biomarker at the start was linked to patients faring worse. This suggests it might be a useful predictor for this particular combination treatment for this type of hard-to-treat pancreatic cancer.\n\n\n### Instructions\nThis annotation task is to identify pieces of information that were lost in the simplification process. Annotate the sample above. Assume that a lay reader only sees the simplification. Identify all things which the reader can NOT learn from the simplification but that they could have learnt from the original.\n\nPlease classify each unit of information into one of the following two categories:\n\n1. Omissions: Pieces of information which were not included in the simplification.\n2. Imprecise/fuzzy concepts: Pieces of information which are included in the simplification, but that have been simplified to the extent that they became imprecise or completely lost their original meaning.\n\nAfterwards, please write a question-answer pair that would elicit the missing information from the original text. Phrase the question in such a way that a reader can understand it without having seen the original text. It should only contain concepts (entities, events, or states) that were mentioned in the simple text, or concepts that have not been directly mentioned but are generally known or inferable from mentioned ones. The answer should be understandable by an average adult, so please explain technical jargon if necessary. Make each question-answer pair as specific as possible and make sure that they are independent of each other. Ask only about one information unit at a time.\n\nA useful heuristic to decide between omissions and imprecise/fuzzy concepts is to see if the question-answer pair clarifies/expands some topic which is discussed in the simplification. If so, classify it as imprecise/fuzzy concepts, otherwise omission.\n\nInclude following elements in your annotation:\n- Original: <exact span in original>\n- Simplification: <exact span in simplification> or null for omissions\n- Rationale: <a short rationale that describes what makes this an information loss>\n- Question: <the question that elicits missing information>\n- Answer: <the answer that provides the missing information from the original span>\n\nStrictly follow the above json format. There can be many omissions and imprecise concepts, so be exhaustive. Use simple language in the answer. Cite the original/simplification span EXACTLY so that span == text[text.index(span):text.index(span)+len(span)]. Output ONLY the json!\n\n### Missing information in simplification [/INST]"], "model": "togethercomputer/llama-2-70b-chat", "model_owner": "", "tags": {}, "num_returns": 1, "args": {"model": "togethercomputer/llama-2-70b-chat", "prompt": "<s>[INST] <<SYS>>\nYou are an expert annotator for outputs of text simplification systems. You are given an example, a sample to annotate and detailed instructions.\n<</SYS>>\n\n\n### Original\nThis study evaluates the effects of vitamin D3 on disease activity and quality of life in ulcerative colitis (UC) patients with hypovitaminosis D. The study was a prospective double-blinded, randomized trial conducted at Community Regional Medical Center, Fresno, CA from 2012\u20132013. Patients with UC and a serum 25(OH)D level <30 ng/ml were eligible for the study. Enrolled subjects were randomized to receive either 2,000 lU or 4,000 IU of oral vitamin D3 daily for a total of 90 days. The Short IBD Questionnaire (SIBDQ) for quality of life, the Partial Mayo Score for UC disease activity and serum lab tests were compared between the two treatment groups.\n\n### Simplification\nThis study looks at whether taking vitamin D3 can affect a particular form of bowel disease (ulcerative colitis) and improve the lives of patients with low levels of vitamin D. The study was carried out at a medical center in Fresno, California, between 2012 and 2013. Patients with this disease and low vitamin D levels were included. Participants were randomly given either 2,000 IU or 4,000 IU of oral vitamin D3 daily for 90 days. Researchers used a survey about participant's quality of life and conducted lab tests between the two groups.\n\n### Missing information in simplification [/INST] [\n    {\n        \"category\": \"imprecise/fuzzy concepts\",\n        \"original\": \"The study was a prospective double-blinded, randomized trial\",\n        \"simplification\": \"The study\",\n        \"rationale\": \"The simplification does not explain the design of the study, it only mentions that it was a 'study'.\",\n        \"question\": \"How did the study control for bias?\",\n        \"answer\": \"The study was double-blinded, so that neither the researcher nor the participants knew which treatment each participant received, and it was randomized, meaning the participants were randomly assigned one of the treatments.\",\n    },\n    {\n        \"category\": \"imprecise/fuzzy concepts\",\n        \"original\": \"a serum 25(OH)D level <30 ng/ml\",\n        \"simplification\": \"low vitamin D levels\",\n        \"rationale\": \"The simplification does not explain the inclusion criteria, namely how low the vitamin D levels of eligible patients were.\",\n        \"question\": \"How low were the vitamin D levels in patients that were included in the study?\",\n        \"answer\": \"Participants in the study all had less than 30ng/ml of vitamin D, which is below the minimum recommendation of vitamin D levels in the body.\"\n    },\n    {\n        \"category\": \"imprecise/fuzzy concepts\",\n        \"original\": \"Short IBD Questionnaire (SIBDQ) for quality of life\",\n        \"simplification\": \"a survey about participant's quality of life\",\n        \"rationale\": \"The specific type of survey (SIBDQ) is not mentioned in the simplification\",\n        \"question\": \"What survey was used to measure participants' quality of life?\",\n        \"answer\": \"The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) was used which gives insights about the physical, social, and emotional status of patients with bowel diseases.\",\n    },\n    {\n        \"category\": \"omission\",\n        \"original\": \"Partial Mayo Score for UC disease activity\",\n        \"simplification\": null,\n        \"rationale\": \"The simplification does not mention that the Partial Mayo Score was used.\",\n        \"question\": \"Besides quality of life survey and the serum tests, what other measures did the researchers use?\",\n        \"answer\": \"The researchers also tracked the partial mayo for UC diseases. UC stands for ulcerative colitis and is an inflammatory bowel disease. The mayo score indicates how active or severe the disease is.\",\n    },\n] </s><s>[INST] ### Original\nBACKGROUND.\nLocally advanced pancreatic cancer (LAPC) is associated with high mortality, and biomarker-driven treatment approach is currently lacking. This study evaluated safety and efficacy of a combination approach of chemotherapy followed by chemo-radiotherapy (CRT) +/\u2212 cetuximab, and the prognostic role of miR-21 in patients with LAPC treated with a multimodality approach.\n\nPATIENTS AND METHODS.\nThis was a randomised phase II trial in which patients with inoperable LAPC were offered gemcitabine and capecitabine (GEM-CAP) for 16 weeks. Patients with stable disease or response after GEM-CAP were randomised to capecitabine or UFT plus radiotherapy (RT) (A), or capecitabine or UFT plus cetuximab plus RT (B). The primary outcome of the study was overall survival (OS). Clinical outcome was compared according to baseline circulating miR-21 levels.\n\nRESULTS.\n17 patients were enrolled and treated with GEM-CAP, with 13 patients achieving disease control and being randomised to arms A (n:7) and B (n:6). After a median follow-up of 61.2 months, median progression free survival (PFS) was 10.4 months and 12.7 months, median OS was 15.8 months and 22.0 months in arms A and B respectively (p > 0.05). Patients with high baseline plasma miR-21 had worse PFS (3.5 vs. 12.7 months; p:0.032) and OS (5.1 vs 15.3 months; p:0.5) compared to patients with low miR-21. Circulating miR-21 levels reflected miR-21 expression within the tissues.\n\nCONCLUSIONS.\nAddition of Cetuximab to CRT following induction chemotherapy did not improve survival. High miR-21 baseline plasma expression was associated with poor clinical outcome in LAPC patients treated with induction chemotherapy followed by chemo-radiotherapy.\n\n### Simplification\nBACKGROUND.\nThis research focused on a type of pancreatic cancer that is hard to treat and often results in death. Specifically, it tested if a combined treatment of chemotherapy and chemo-radiotherapy with or without an extra drug called cetuximab would help. It also checked if a biomarker (something in your body that can be measured to show the presence of disease), called miR-21, could predict how patients would respond to the treatment.\n\nPATIENTS AND METHODS.\nIn this trial, patients who couldn't undergo surgery for their pancreatic cancer were given a specific combination of drugs for 16 weeks. Only patients whose cancer didn't worsen or even improved after this initial treatment were then given another drug either with or without cetuximab in combination with radiotherapy. The key measure of success was overall survival rate. They also compared people's response to the treatment based on their levels of the biomarker miR-21.\n\nRESULTS.\n17 patients took the initial drugs, and 13 of them improved enough to receive the extra treatments. After about 5 years, they recorded how long it took for patients' cancers to get worse and how long the patients lived overall. They didn't see a big difference whether patients received the extra drug cetuximab or not. They did find that patients with high levels of the biomarker miR-21 generally did worse compared to those with lower levels, in terms of both how quickly their cancer got worse and how long they lived.\n\nCONCLUSIONS.\nAdding cetuximab to the chemo-radiotherapy after the initial combination drug treatment didn't seem to improve survival rates. Having a high level of the miR-21 biomarker at the start was linked to patients faring worse. This suggests it might be a useful predictor for this particular combination treatment for this type of hard-to-treat pancreatic cancer.\n\n\n### Instructions\nThis annotation task is to identify pieces of information that were lost in the simplification process. Annotate the sample above. Assume that a lay reader only sees the simplification. Identify all things which the reader can NOT learn from the simplification but that they could have learnt from the original.\n\nPlease classify each unit of information into one of the following two categories:\n\n1. Omissions: Pieces of information which were not included in the simplification.\n2. Imprecise/fuzzy concepts: Pieces of information which are included in the simplification, but that have been simplified to the extent that they became imprecise or completely lost their original meaning.\n\nAfterwards, please write a question-answer pair that would elicit the missing information from the original text. Phrase the question in such a way that a reader can understand it without having seen the original text. It should only contain concepts (entities, events, or states) that were mentioned in the simple text, or concepts that have not been directly mentioned but are generally known or inferable from mentioned ones. The answer should be understandable by an average adult, so please explain technical jargon if necessary. Make each question-answer pair as specific as possible and make sure that they are independent of each other. Ask only about one information unit at a time.\n\nA useful heuristic to decide between omissions and imprecise/fuzzy concepts is to see if the question-answer pair clarifies/expands some topic which is discussed in the simplification. If so, classify it as imprecise/fuzzy concepts, otherwise omission.\n\nInclude following elements in your annotation:\n- Original: <exact span in original>\n- Simplification: <exact span in simplification> or null for omissions\n- Rationale: <a short rationale that describes what makes this an information loss>\n- Question: <the question that elicits missing information>\n- Answer: <the answer that provides the missing information from the original span>\n\nStrictly follow the above json format. There can be many omissions and imprecise concepts, so be exhaustive. Use simple language in the answer. Cite the original/simplification span EXACTLY so that span == text[text.index(span):text.index(span)+len(span)]. Output ONLY the json!\n\n### Missing information in simplification [/INST]", "top_p": 1, "top_k": 1, "temperature": 0, "max_tokens": 1553, "stop": ["[/INST]", "</s>"], "repetition_penalty": 1, "logprobs": null}, "subjobs": [], "choices": [{"text": " [\n  {\n    \"category\": \"omission\",\n    \"original\": \"BACKGROUND\",\n    \"simplification\": null,\n    \"rationale\": \"The simplification does not provide any background information about the study or the disease being studied.\",\n    \"question\": \"What is the context of this study?\",\n    \"answer\": \"The study is focused on a type of pancreatic cancer that is hard to treat and often results in death. The researchers were testing if a combined treatment of chemotherapy and chemo-radiotherapy with or without an extra drug called cetuximab would help.\"\n  },\n  {\n    \"category\": \"imprecise/fuzzy concepts\",\n    \"original\": \"Locally advanced pancreatic cancer (LAPC) is associated with high mortality, and biomarker-driven treatment approach is currently lacking.\",\n    \"simplification\": \"This research focused on a type of pancreatic cancer that is hard to treat and often results in death.\",\n    \"rationale\": \"The simplification does not explain the specific type of cancer being studied or the issue with current treatment approaches.\",\n    \"question\": \"What is the specific type of pancreatic cancer being studied?\",\n    \"answer\": \"The study is focused on locally advanced pancreatic cancer (LAPC), which is a type of pancreatic cancer that has spread to nearby tissues and is difficult to treat.\"\n  },\n  {\n    \"category\": \"omission\",\n    \"original\": \"Patients with stable disease or response after GEM-CAP were randomised to capecitabine or UFT plus radiotherapy (RT) (A), or capecitabine or UFT plus cetuximab plus RT (B).\",\n    \"simplification\": null,\n    \"rationale\": \"The simplification does not mention the specific treatment groups or the randomization process.\",\n    \"question\": \"How were the patients divided into treatment groups?\",\n    \"answer\": \"The patients were divided into two treatment groups: one group received capecitabine or UFT plus radiotherapy (RT), and the other group received capecitabine or UFT plus cetuximab plus RT.\"\n  },\n  {\n    \"category\": \"imprecise/fuzzy concepts\",\n    \"original\": \"Clinical outcome was compared according to baseline circulating miR-21 levels.\",\n    \"simplification\": \"They compared people's response to the treatment based on their levels of the biomarker miR-21.\",\n    \"rationale\": \"The simplification does not explain what specific clinical outcomes were measured or how they were compared.\",\n    \"question\": \"What specific clinical outcomes were measured in the study?\",\n    \"answer\": \"The study measured overall survival (OS) and progression-free survival (PFS) as clinical outcomes.\"\n  },\n  {\n    \"category\": \"omission\",\n    \"original\": \"High miR-21 baseline plasma expression was associated with poor clinical outcome in LAPC patients treated with induction chemotherapy followed by chemo-radiotherapy.\",\n    \"simplification\": null,\n    \"rationale\": \"The simplification does not mention the specific outcome that was associated with high miR-21 levels.\",\n    \"question\": \"What was the specific outcome associated with high miR-21 levels?\",\n    \"answer\": \"The study found that high levels of miR-21 in the blood were associated with poor clinical outcomes, such as shorter overall survival and progression-free survival, in patients with locally advanced pancreatic cancer who received induction chemotherapy followed by chemo-radiotherapy.\"\n  }\n]", "finish_reason": "stop"}], "usage": {"prompt_tokens": 2541, "completion_tokens": 853, "total_tokens": 3394}}